New combo therapy aims to boost stomach cancer treatment before surgery
NCT ID NCT03776487
First seen Nov 03, 2025 · Last updated May 15, 2026 · Updated 26 times
Summary
This study tests whether combining two immunotherapy drugs (nivolumab and ipilimumab) with chemotherapy and radiation before surgery can safely treat stomach cancer. About 32 adults with resectable gastric or gastroesophageal junction cancer will receive this combination. The goal is to see if the treatment shrinks tumors and improves outcomes without causing severe side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLINICAL STAGE III GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.